With the Nikkei Average experiencing extreme volatility, pharmaceutical companies are reportedly looking for signs that their share prices have bottomed out. Against a backdrop of investor interest in changing market conditions, the performance of individual stocks is attracting attention.
This article reports that, in contrast to the Nikkei Average’s volatile movements, pharmaceutical companies are attempting to find a bottom for their share prices. It also describes investors’ efforts to determine which stocks to choose.
The author does not provide explicit investment guidance, leaving readers to await further developments as they take in the information.